Brian Robert Champion

Brian Robert Champion, based in Abingdon, GB, is a prolific inventor with a remarkable portfolio of 22 patents. His work primarily focuses on oncolytic virus therapies, showcasing innovative approaches to cancer treatment. Champion's research combines advanced virology techniques with the potential for targeted immunotherapy, marking significant contributions to the field.

Latest Patents

Among Champion’s notable patents is the innovative "Oncolytic group B adenovirus expressing a stroma-targeted bispecific T-cell engager." This modified adenovirus, referred to as Enadenotucirev (EnAd), is engineered with a bispecific T-cell activator that includes at least two binding domains, one of which targets a specific surface antigen on T-cells. The patent encompasses pharmaceutical formulations featuring the virus and its applications for treating cancer, along with the processes for preparing it.

Another significant patent is related to the "Group B adenovirus encoding an anti-TCR-complex antibody or fragment." This disclosure pertains to a replication-deficient or replication-capable group B oncolytic adenovirus, selected from the group consisting of Ad11 and Enadenotucirev. The virus encodes an antibody or a binding fragment for cancer cell expression, specifically targeting the CD3 protein of the T-cell receptor complex, excluding the encoding of B7 protein.

Career Highlights

Brian Robert Champion's career includes key positions at notable companies such as Psioxus Therapeutics Limited and Pfizer Vaccines, LLC. His role in these organizations has been integral to advancing oncolytic virus research and developing therapeutic solutions for cancer patients.

Collaborations

Throughout his career, Champion has collaborated with renowned professionals in the field, including Alice Claire Noel Brown and David Michael Wyatt. These partnerships have contributed to the success of his innovative projects and patents.

Conclusion

Brian Robert Champion stands out as a significant figure in the realm of oncolytic virus therapy. His extensive patent portfolio and collaborative efforts with prominent companies and fellow innovators underscore his dedication to advancing cancer treatment methodologies. As Champion continues to explore the potential of oncolytic viruses, he remains a vital contributor to the future of medical science.

This text is generated by artificial intelligence and may not be accurate.